Ten pharmaceutical companies are among the 100 best companies for working mothers, according to Working Mother magazine.
Ten pharmaceutical companies are among the 100 best companies for working mothers, according to Working Mother magazine.
Working Mother rated the nation's companies according to pay, opportunities for advancement, child care, flexibility, family-friendly benefits and work/life support. Researchers for the magazine discovered that companies are offering more ways to meet employees' dependent care needs, encouraging greater use of in-place flexible scheduling and telecommuting, and implementing policies to help women climb their corporations' ladders.
They also noted that companies are working harder at providing better amenities, such as on-site cafeterias and fitness centers.
The results appear in the October issue of the magazine.
For the thirteenth year - as long as Working Mother has been naming a top 100 - Johnson & Johnson and Merck & Co. were named top companies for working women.
Of Johnson & Johnson's 34,519 employees, 16,914 (49%) are women; of Merck's 32,527 employees, 17, 174 (53%) are women.
Hoffman-LaRoche Inc. was named to the list for the eighth time, after a brief absence. The company which employs 5,611 employees, has a female work force of 2,562, or 50%.
It was reintroduced to the list this year after it developed a formal policy requiring top management to devise strategies for the development of its high-potential women. Working Mother applauded the program for improving women's chances for career advancement.
"There's a war for talent in the pharmaceutical industry, so being named among the top companies for working mothers is extremely meaningful for Roche," said Stephen Grossman, vice president of human resources for Hoffman-LaRoche.
Glaxo Wellcome made the list for the seventh time and Eli Lilly, Warner Lambert and DuPont Pharmaceuticals found themselves on the list for the fourth time. Newcomers included Bristol-Myers Squibb, American Home Products and Pfizer Labs. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.